Adult primary glomerular diseases due to podocytopathies: a single center experience on patient characteristics, treatment and outcomes

Basit Öğe Kaydı
dc.authoridSarsik Kumbaraci, Banu/0000-0003-4775-3942
dc.contributor.authorBulgur, Ismail
dc.contributor.authorSen, Sait
dc.contributor.authorKumbaraci, Banu Sarsik
dc.contributor.authorDemirci, Meltem Sezis
dc.contributor.authorYilmaz, Mumtaz
dc.contributor.authorAsci, Gulay
dc.date.accessioned2024-08-31T07:50:04Z
dc.date.available2024-08-31T07:50:04Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose: This study aims to evaluate the demographic, clinical, and pathologic characteristics and response to immunosuppressive therapy, particularly corticosteroids, in adult patients with primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), which are classified as podocytopathies. Materials and Methods: Between January 1998 and December 2014, this study included 44 patients (27 with primary FSGS and 17 with MCD) aged older than 18 years with a histopathologic diagnosis, symptoms of nephrotic syndrome, and a minimum follow-up of six months. Patients were divided into two groups according to the treatment they received and three groups according to their response to treatment. Patients diagnosed with primary FSGS and MCD were evaluated based on clinical, demographic, and laboratory findings, as well as response to treatment, and a comparison was conducted between the two groups. Results: 59.1% of the patients were male with a mean age of 44.8 +/- 17.7 years. At the time of diagnosis, there were no statistically significant differences in clinical and demographic characteristics between MCD and primary FSGS patients. However, in patients with MCD, the mean creatinine clearance (118.0 +/- 46.7 ml/min) was higher and the rate of microscopic hematuria (11.8%) was lower at the time of diagnosis. There was an increased need for alternative immunosuppressive treatments besides corticosteroids in patients with primary FSGS to achieve partial or complete remission. At both the third and sixthmonth follow-ups, MCD patients achieved a higher rate of complete remission (proteinuria <0.3 g/day) than FSGS patients. Conclusion: Compared to MCD, primary FSGS is more likely to progress, requires more immunosuppressive therapy beyond corticosteroids to achieve partial or complete remission, and has a lower treatment response rate.en_US
dc.identifier.endpage30en_US
dc.identifier.issn2602-3032
dc.identifier.issn2602-3040
dc.identifier.issue1en_US
dc.identifier.startpage21en_US
dc.identifier.urihttps://hdl.handle.net/11454/105102
dc.identifier.volume49en_US
dc.identifier.wosWOS:001196955900009en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherCukurova Univ, Fac Medicineen_US
dc.relation.ispartofCukurova Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectPodocytopathyen_US
dc.subjectPrimary Focal Segmental Glomerulosclerosisen_US
dc.subjectMinimal Change Diseaseen_US
dc.subjectProteinuriaen_US
dc.subjectPrognosisen_US
dc.titleAdult primary glomerular diseases due to podocytopathies: a single center experience on patient characteristics, treatment and outcomesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu